Enzalutamide patent expiry?

See the DrugPatentWatch profile for Enzalutamide

When does Enzalutamide's patent expire?

Enzalutamide, a medication used to treat prostate cancer, is patented by Astellas Pharma, a Japanese pharmaceutical company. According to DrugPatentWatch.com, Enzalutamide's patents are set to expire in different countries between 2025 and 2030 [1].

Why is Astellas Pharma facing patent challenges?

Astellas Pharma, the manufacturer of Enzalutamide, is facing patent challenges from generic manufacturers, such as Sandoz and Mylan, which have filed Abbreviated New Drug Applications (ANDAs) with the FDA to market a generic version of the medication [2].

What are the implications of patent expiry for Enzalutamide sales?

The expiry of Enzalutamide's patents will allow generic manufacturers to enter the market, which may lead to increased competition and decreased sales for Astellas Pharma. However, the company has taken steps to extend its market exclusivity through various means, including the development of a new, orally administered version of Enzalutamide [3].

Will Enzalutamide's biosimilars enter the market before patent expiry?

It's unlikely that biosimilars will enter the market before Enzalutamide's patent expiry, as biosimilar development processes typically take several years. However, biosimilars may be approved shortly after patent expiry, which could further erode market share for Astellas Pharma [4].

How will generic competition impact Enzalutamide prices?

The entry of generic competition is likely to lead to lower prices for Enzalutamide, as generic manufacturers will operate on tighter profit margins. This could benefit patients, who may face lower out-of-pocket costs for the medication [5].

Sources:

[1] DrugPatentWatch.com. (n.d.). Enzalutamide Patent Expiry Date. Retrieved from https://www.drugpatentwatch.com/drug/Enzalutamide/

[2] FDA. (2020). ANDA Approvals. Retrieved from https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-therapeutic-biologics/anda-approvals

[3] Astellas Pharma. (2020). Xtandi (Enzalutamide) Oral Capsules. Retrieved from https://www.astellas.com/en/xtandi

[4] FDA. (2020). Biosimilar Development. Retrieved from https://www.fda.gov/drugs/biosimilars/development

[5] GoodRx. (2022). Enzalutamide (Xtandi) Cost & Coupons. Retrieved from https://www.goodrx.com/enzalutamide

Note: The above information is subject to change and may not reflect the most up-to-date information on Enzalutamide's patent expiry.